| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Richard A. Edlin last filed a Form 4 in March 2023, as Director at EGRX. Richard A. Edlin's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 22,600 shares of EGRX. The EGRX filings lean toward selling, a net 800 shares.
Richard A. Edlin has 9 Form 4 filings on record from March 2017 to March 2023, all as Director at Eagle Pharmaceuticals (EGRX), 2017–2023.
The 9 reported transactions were 7 option or other derivative awards, 1 open-market sale and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $477K and 1 sale worth about $211K.
The only open-market purchase was 6,000 shares of EGRX at an average $79.44 on March 22, 2017, about $477K.
The only open-market sale was 6,800 shares of EGRX at an average $30.99 on September 6, 2022, about $211K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.